-+ 0.00%
-+ 0.00%
-+ 0.00%

Tianyu Co., Ltd. (300702.SZ) subsidiary sidiglitine phosphate API passed CDE review

Zhitongcaijing·09/04/2026 10:57:09
Listen to the news

According to Zhitong Finance App, Tianyu Co., Ltd. (300702.SZ) issued an announcement. Zhejiang Jingsheng Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, recently passed the review of the drug evaluation center of the China Drug Administration (“CDE”). Sitagliptin phosphate is a hypoglycemic drug that helps control blood sugar levels and is mainly used to treat type 2 diabetes. The raw drug sitagliptin phosphate has now passed the CDE review, and it is still necessary to obtain the announcement that the GMP compliance test results “meet the requirements” from the Zhejiang Drug Administration before it can be marketed and sold domestically.